Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 3/2011

Open Access 01-12-2011 | Review

Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths

Authors: Mehnaz Jabeen, Mohammad Yawar Yakoob, Aamer Imdad, Zulfiqar A Bhutta

Published in: BMC Public Health | Special Issue 3/2011

Login to get access

Abstract

Background

Pre-eclampsia and Eclampsia are relatively common complications of pregnancy, leading to considerable maternal and fetal mortality and morbidity. We sought to review the effect of aspirin, calcium supplementation, antihypertensive agents and magnesium sulphate on risk stillbirths.

Methods

A systematic literature search was conducted to identify studies evaluating the above interventions. We used a standardized abstraction and grading format and performed meta-analyses where data were available from more than one studies. The estimated effect on stillbirths was determined by applying the standard Child Health Epidemiology Reference Group (CHERG) rules for multiple outcomes. For interventions with insufficient evidence for overall effect, a Delphi process was undertaken to estimate effectiveness.

Results

We identified 82 relevant studies. For aspirin, maganesium sulphate and use of antihypertensive we found an insignificant decrease in stillbirth and perinatal mortality. For calcium supplementation, there was a borderline significant reduction in stillbirths (RR 0.81, 95 % CI 0.63-1.03). We undertook a Delphi consultation among experts to assess the potential impact of a package of interventions for the management of pre-eclampsia and eclampsia (antihypertensive, magnesium sulphate and C-section if needed). The Delphi process suggested 20% reduction each in both antepartum and intrapartum stillbirths with the use of this package.

Conclusions

Despite promising benefits of calcium supplementation and aspirin use cases on maternal morbidity and eclampsia in high risk cases, further work is needed to ascertain their benefits in relation to stillbirths. The Delphi process undertaken for assessing potential impact of a package of interventions indicated that this could be associated with 20% reduction in stillbirths, for input into LiST.
Appendix
Available only for authorised users
Literature
1.
Yu CKH, P AT, parra M, Palma Das R, Nicolaides KH: Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine Doppler at 23 weeks gestation. Ultrasound in Obstetrics & Gynecology. 2003, 22: 233-239. 10.1002/uog.218.CrossRef
2.
Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet. 2006, 367 (9516): 1066-1074. 10.1016/S0140-6736(06)68397-9.CrossRefPubMed
3.
Abalos E, Duley L, Steyn DW, Henderson-Smart DJ: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007, CD002252-1
4.
Italian Study of Aspirin in Pregnancy: Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet. 1993, 341 (8842): 396-400.
5.
Ananth CV, Basso O: Impact of pregnancy-induced hypertension on stillbirth and neonatal mortality. Epidemiology. 2010, 21 (1): 118-123. 10.1097/EDE.0b013e3181c297af.PubMedCentralCrossRefPubMed
6.
Norwitz ER, Repke JT: Preeclampsia prevention and management. J Soc Gynecol Investig. 2000, 7 (1): 21-36. 10.1016/S1071-5576(99)00050-7.CrossRefPubMed
7.
Ronsmans C, Campbell O: Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy. BMC Public Health.
8.
Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010, CD001059-8
9.
Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J: Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002, 109 (2): 161-167. 10.1111/j.1471-0528.2002.01046.x.CrossRefPubMed
10.
Wide-Swensson DH, Ingemarsson I, Lunell NO, Forman A, Skajaa K, Lindberg B, Lindeberg S, Marsal K, Andersson KE: Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol. 1995, 173 (3 Pt 1): 872-878. 10.1016/0002-9378(95)90357-7.CrossRefPubMed
11.
Tulppala M, Marttunen M, Soderstrom-Anttila V, Foudila T, Ailus K, Palosuo T, Ylikorkala O: Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod. 1997, 12 (7): 1567-1572. 10.1093/humrep/12.7.1567.CrossRefPubMed
12.
Uzan S, Beaufils M, Breart G, Bazin B, Capitant C, Paris J: Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet. 1991, 337 (8755): 1427-1431. 10.1016/0140-6736(91)93124-R.CrossRefPubMed
13.
Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, Barkai G, Ben-Baruch G, Yahal I, Blankstein J, et al: The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989, 321 (6): 351-356. 10.1056/NEJM198908103210603.CrossRefPubMed
14.
Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990, 162 (4): 960-966. discussion 966-967CrossRefPubMed
15.
Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, Paul RH, Romero R, Witter F, Rosen M, et al: Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993, 329 (17): 1213-1218. 10.1056/NEJM199310213291701.CrossRefPubMed
16.
Wallenburg HC, Dekker GA, Makovitz JW, Rotmans N: Effect of low-dose aspirin on vascular refractoriness in angiotensin-sensitive primigravid women. Am J Obstet Gynecol. 1991, 164 (5 Pt 1): 1169-1173.CrossRefPubMed
17.
Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, Uzan S, Marquis P, Parmentier D, Churlet A: Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1). BJOG. 2003, 110 (5): 475-484.PubMed
18.
Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O: Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol. 1993, 100 (9): 809-815. 10.1111/j.1471-0528.1993.tb14304.x.CrossRefPubMed
19.
Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P: Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet. 1986, 1 (8471): 1-3. 10.1016/S0140-6736(86)91891-X.CrossRefPubMed
20.
Bhutta ZA, Ali S, Cousens S, Ali TM, Haider BA, Rizvi A, Okong P, Bhutta SZ, Black RE: Alma-Ata: Rebirth and Revision 6 Interventions to address maternal, newborn, and child survival: what difference can integrated primary health care strategies make?. Lancet. 2008, 372 (9642): 972-989. 10.1016/S0140-6736(08)61407-5.CrossRefPubMed
21.
Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D: Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010, 11: CD000025-PubMed
22.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al: Grading quality of evidence and strength of recommendations. BMJ. 2004, 328 (7454): 1490-10.1136/bmj.328.7454.1490.CrossRefPubMed
23.
Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S: Standards for CHERG reviews of intervention effects on child survival. Int J Epidemiol. 2010, 39 (Suppl 1): i21-31. 10.1093/ije/dyq036.PubMedCentralCrossRefPubMed
24.
Hofmeyr GJ, Atallah AN, Duley L: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006, 3: CD001059-PubMed
25.
Duley L, Henderson-Smart DJ, Meher S, King JF: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007, CD004659-2
26.
Duley L, Gulmezoglu AM, Henderson-Smart DJ: Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2003, CD000025-2
27.
Kincaid-Smith P: Trial to evaluate the role of aspirin (60mg) in the prevention of idiopathic intrauterine growth retardation and pregnancy induced hypertension in primigravid women with abnormal uterine artery waveforms on Doppler examination at 22-24 weeks gestation. Personal communication. 1996
28.
Gallery EDM, R M, Hawkins M, Leslie GI, Gyory AZ: Low-dose aspirin in high-risk pregnancy. 1997, 16: 229-238.
29.
Schrocksnadel H, Sitte B, Alge A, Steckel-Berger G, Schwegel P, Pastner E, Daxenbichler G, Hansen H, Dapunt O: Low-dose aspirin in primigravidae with positive roll-over test. Gynecol Obstet Invest. 1992, 34 (3): 146-150. 10.1159/000292748.CrossRefPubMed
30.
Rotchell YE, Cruickshank JK, Gay MP, Griffiths J, Stewart A, Farrell B, Ayers S, Hennis A, Grant A, Duley L, et al: Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol. 1998, 105 (3): 286-292. 10.1111/j.1471-0528.1998.tb10088.x.CrossRefPubMed
31.
ECPPA (Estudo Colaborativo para Prevencao da Pre-eclampsia com Aspirina) Collaborative Group: ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br J Obstet Gynaecol. 1996, 103 (1): 39-47. 10.1111/j.1471-0528.1996.tb09513.x.CrossRef
32.
Zimmermann P, E V, Koskinen J, Niemi K, Nyman R, Kujansuu E: Effect of low dose aspirin treatment on vascular resistance in the uterine, uteroplacental, renal and umbilical arteries - a prospective longitudinal study on a high risk population with persistent notch in the uterine arteries. European Journal of Ultrasound. 1997, 5: 17-30. 10.1016/S0929-8266(96)00203-0.CrossRef
33.
Caspi E, Raziel A, Sherman D, Arieli S, Bukovski I, Weinraub Z: Prevention of pregnancy-induced hypertension in twins by early administration of low-dose aspirin: a preliminary report. Am J Reprod Immunol. 1994, 31 (1): 19-24.CrossRefPubMed
34.
Dekker GA: Prediction and prevention of pregnancy-induced hypertensive disorders: a clinical and pathophysiologic study [MD thesis]. 1989
35.
McParland P, Pearce JM, Chamberlain GV: Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet. 1990, 335 (8705): 1552-1555. 10.1016/0140-6736(90)91377-M.CrossRefPubMed
36.
Hauth JC, Goldenberg RL, Parker CR, Philips JB, Copper RL, DuBard MB, Cutter GR: Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol. 1993, 168 (4): 1083-1091. discussion 1091-1083CrossRefPubMed
37.
August P, H G, Edersheim TG, Hutson JM, Druzin M: Sustained release, low-dose aspirin ameliorates but does not prevent preeclampsia (PE) in a high risk population. Proceedings of 9th International Congress, International Society for the Study of Hypertension in Pregnancy. 1994, Sydney, Australia, 72-
38.
Beaufils M, Uzan S, Donsimoni R, Colau JC: Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985, 1 (8433): 840-842. 10.1016/S0140-6736(85)92207-X.CrossRefPubMed
39.
Rogov V, T I, Sidorova S, Androsova S: Prevention of pregnancy complications with acetylsalicylic acid (ASA) and dipyridamol (DP) in women with chronic glomerulonephritis (CGN) and essential hypertension (EH). Proceedings of 9th International Congress of the International Society for the Study of Hypertension in Pregnancy. 1994, Sydney, Australia, 280-
40.
Railton A, D A: Aspirin and dipyridamole in the prevention of pre-eclampsia: effect on plasma prostanoids 6 keto PG1a and TXB2 and clinical outcome of pregnancy. Proceedings of the 6th International Congress of the International Society for the Study of Hypertension in Pregnancy. 1988, Montreal, Quebec, Canada
41.
Byaruhanga RN, C T, Rusakaniko S: A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. International Journal of Gynecology & Obstetrics. 1998, 60: 129-135. 10.1016/S0020-7292(97)00257-9.CrossRef
42.
Davies NJ, G M, Farquharson RG, Walkinshaw SA: Low-dose aspirin in the prevention of hypertensive disorders of pregnancy in relatively low-risk nulliparous women. Hypertension in Pregnancy. 1995, 14: 49-55. 10.3109/10641959509058050.CrossRef
43.
Golding J: A randomised trial of low dose aspirin for primiparae in pregnancy. The Jamaica Low Dose Aspirin Study Group. Br J Obstet Gynaecol. 1998, 105 (3): 293-299. 10.1111/j.1471-0528.1998.tb10089.x.CrossRefPubMed
44.
CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group: CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 1994, 343 (8898): 619-629. 10.1016/S0140-6736(94)92633-6.CrossRef
45.
Michael CA, W B: Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. Maternal physiology and pathology Low-dose aspirin in the prevention of pre-eclampsia: current evaluation. Edited by: Teoh ES, Ratnam SS, Macnaughton MC. 1993, 183-
46.
Morris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ: A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol. 1996, 87 (1): 74-78. 10.1016/0029-7844(95)00340-1.CrossRefPubMed
47.
Rogers MS, Fung HY, Hung CY: Calcium and low-dose aspirin prophylaxis in women at high risk of pregnancy-induced hypertension. Hypertens Pregnancy. 1999, 18 (2): 165-172. 10.3109/10641959909023076.CrossRefPubMed
48.
Wang Z, Li W: A prospective randomized placebo-controlled trial of low-dose aspirin for prevention of intra-uterine growth retardation. Chin Med J (Engl). 1996, 109 (3): 238-242.
49.
Ebrashy A, I M, Marzook A, Yousef D: Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croatian Medical Journal. 2005, 46: 826-PubMed
50.
Volpicelli T, D'Anto V, Faticato A, Galante L, Civitillo RM, Rappa C: Gestosi '99. 1999, 159-
51.
Hermida RC, A D, Iglesias M, Mojon A, Silva I, Ucieda R: Time-dependant effects of low dose aspirin administration on blood pressure in pregnant women. Hypertension. 1997, 30: 589-CrossRefPubMed
52.
Ramaiya C, Mgaya HN: Low dose aspirin in prevention of pregnancy-induced hypertension in primigravidae at the Muhimbili Medical Center, Dar es Salaam. East Afr Med J. 1995, 72 (11): 690-693.PubMed
53.
Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, et al: Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998, 338 (11): 701-705. 10.1056/NEJM199803123381101.CrossRefPubMed
54.
Rivas-Echeverria CA, E Y, Molina L, Novoa D: Synergic use of aspirin, fish oil and vitamins C and E for the prevention of preeclampsia. 2000, 19: 30-
55.
JM B: Prevention of hypertensive disorders of pregnancy with calcium supplementation. 8th World Congress on Hypertension in Pregnancy; 1992 November 8-12;. 1991, Buenos Aires
56.
Kumar A, Devi SG, Batra S, Singh C, Shukla DK: Calcium supplementation for the prevention of pre-eclampsia. Int J Gynaecol Obstet. 2009, 104 (1): 32-36. 10.1016/j.ijgo.2008.08.027.CrossRefPubMed
57.
Villar J, A AH, Merialdi M, Mathai M, Ali M, Zavaleta N, et al: World Health Organisation randomized trial of calcium supplementation among low calcium intake pregnant women. American Journal of Obstetrics and Gynecology. 2006, 194: 639-10.1016/j.ajog.2006.01.068.CrossRefPubMed
58.
Kahhale S, Z M, Carrara W, Paula FJ, Sabbaga E, Neme B: Comparative study of chronic hypertensive pregnant women treated and non-treated with pindolol. Ginecologia e Obstetrícia Brasileiras. 1985, 8: 85-
59.
DJ N: Evaluation of the use of Verapamil with non-serious form of chronic vascular hypertension disease during pregnancy Doctoral thesis. 2000
60.
Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon H, Berchel C: A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Br J Obstet Gynaecol. 1990, 97 (2): 134-141. 10.1111/j.1471-0528.1990.tb01738.x.CrossRefPubMed
61.
Blake S, MacDonald D: The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment. Br J Obstet Gynaecol. 1991, 98 (3): 244-248. 10.1111/j.1471-0528.1991.tb13387.x.CrossRefPubMed
62.
Bott-Kanner G, H M, Friedman S, Boner G, Ovadia J, Merlob P, et al: Antihypertensive therapy in the management of hypertension in pregnancy - a clinical double-blind study of pindolol. Clinical and Experimental Hypertension. 1992, B11: 207-
63.
Gruppo di Studio Ipertensione in Gravidanza: Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Gruppo di Studio Ipertensione in Gravidanza. Br J Obstet Gynaecol. 1998, 105 (7): 718-722. 10.1111/j.1471-0528.1998.tb10201.x.
64.
Odendaal HJ, S I, Pattinson RC: Prazosin for the treatment of hypertension in pregnancy: a randomized control trial. Oxford Database of Perinatal Trials, Version 12. Edited by: Autumn Chalmers I. 1991, Oxford: Oxford University Press, Disk Issue 6
65.
Wichman K, Ryden G, Karlberg BE: A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. Scand J Clin Lab Invest Suppl. 1984, 169: 90-95. 10.3109/00365518409085385.CrossRefPubMed
66.
Hogstedt S, Lindeberg S, Axelsson O, Lindmark G, Rane A, Sandstrom B, Lindberg BS: A prospective controlled trial of metoprolol-hydralazine treatment in hypertension during pregnancy. Acta Obstet Gynecol Scand. 1985, 64 (6): 505-510. 10.3109/00016348509156729.CrossRefPubMed
67.
Redman CW: Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet. 1976, 2 (7989): 753-756. 10.1016/S0140-6736(76)90597-3.CrossRefPubMed
68.
Walker JJ, C A, Erwin L, Calder AA: Labetalol in pregnancy-induced hypertension: fetal and maternal effects. International Congress Series 591 Amsterdam: Excerpta Medica. Edited by: Reilly A, Symonds EM. 1982, 148-
69.
Rubin PC, Butters L, Clark DM, Reynolds B, Sumner DJ, Steedman D, Low RA, Reid JL: Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983, 1 (8322): 431-434.PubMed
70.
71.
Cruickshank DJ, R A, Campbell DM, MacGillivray I: Maternal obstetric outcome measures in a randomised controlled study of labetalol in the treatment of hypertension in pregnancy. Clinical and Experimental Hypertension. 1991, B10: 333-
72.
Sibai BM, Gonzalez AR, Mabie WC, Moretti M: A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol. 1987, 70 (3 Pt 1): 323-327.PubMed
73.
Sibai BM, Barton JR, Akl S, Sarinoglu C, Mercer BM: A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992, 167 (4 Pt 1): 879-884.CrossRefPubMed
74.
Rosenfeld J, Bott-Kanner G, Boner G, Nissenkorn A, Friedman S, Ovadia J, Merlob P, Reisner S, Paran E, Zmora E, et al: Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur J Obstet Gynecol Reprod Biol. 1986, 22 (4): 197-204. 10.1016/0028-2243(86)90066-3.CrossRefPubMed
75.
Paran E, Holzberg G, Mazor M, Zmora E, Insler V: Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. Int J Clin Pharmacol Ther. 1995, 33 (2): 119-123.PubMed
76.
Catalano D, E S, Pollio F, Ascione L, Russo C, De Santi B, et al: Evaluation of nifedipine monotherapy in the management of pregnancy hypertension. Giornale Italiano Di Ostetricia e Ginecologia. 1997, 6: 373-
77.
Elhassan EM, Mirghani OA, Habour AB, Adam I: Methyldopa versus no drug treatment in the management of mild pre-eclampsia. East Afr Med J. 2002, 79 (4): 172-175.CrossRefPubMed
78.
Leather HM, Humphreys DM, Baker P, Chadd MA: A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet. 1968, 2 (7566): 488-490. 10.1016/S0140-6736(68)90650-8.CrossRefPubMed
79.
Pickles CJ, Broughton Pipkin F, Symonds EM: A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol. 1992, 99 (12): 964-968. 10.1111/j.1471-0528.1992.tb13698.x.CrossRefPubMed
80.
Weitz C, Khouzami V, Maxwell K, Johnson JW: Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987, 25 (1): 35-40. 10.1016/0020-7292(87)90181-0.CrossRefPubMed
81.
Arias F, Zamora J: Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Obstet Gynecol. 1979, 53 (4): 489-494.PubMed
82.
Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002, 359 (9321): 1877-1890. 10.1016/S0140-6736(02)08778-0.CrossRefPubMed
83.
Moodley J, M J: Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large randomized trial. 1994, 13: 245-252.
84.
Coetzee EJ, Dommisse J, Anthony J: A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol. 1998, 105 (3): 300-303. 10.1111/j.1471-0528.1998.tb10090.x.CrossRefPubMed
85.
Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM: Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol. 2003, 101 (2): 217-220. 10.1016/S0029-7844(02)03053-3.CrossRefPubMed
86.
Witlin AG, Friedman SA, Sibai BM: The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1997, 176 (3): 623-627. 10.1016/S0002-9378(97)70558-1.CrossRefPubMed
87.
Chen FP, Chang SD, Chu KK: Expectant management in severe preeclampsia: does magnesium sulfate prevent the development of eclampsia?. Acta Obstet Gynecol Scand. 1995, 74 (3): 181-185. 10.3109/00016349509008935.CrossRefPubMed
88.
Lawn JE, Yakoob MY, Haws RA, Soomro T, Darmstadt GL, Bhutta ZA: 3.2 million stillbirths: epidemiology and overview of the evidence review. BMC Pregnancy Childbirth. 2009, 9 (Suppl 1): S2-10.1186/1471-2393-9-S1-S2.PubMedCentralCrossRefPubMed
89.
Mbah AK, Alio AP, Marty PJ, Bruder K, Whiteman VE, Salihu HM: Pre-eclampsia in the first pregnancy and subsequent risk of stillbirth in black and white gravidas. Eur J Obstet Gynecol Reprod Biol. 2010, 149 (2): 165-169. 10.1016/j.ejogrb.2009.12.035.CrossRefPubMed
90.
Miller EC, Cao H, Wen SW, Yang Q, Lafleche J, Walker M: The risk of adverse pregnancy outcomes is increased in preeclamptic women who smoke compared with nonpreeclamptic women who do not smoke. Am J Obstet Gynecol. 2010, 203 (4): 334 e331-338. 10.1016/j.ajog.2010.05.020.CrossRef
91.
Onyiriuka AN: Analysis of stillbirths in a Nigerian mission hospital. Nig Q J Hosp Med. 2009, 19 (1): 27-31.PubMed
92.
Hossain N, Khan N, Khan NH: Obstetric causes of stillbirth at low socioeconomic settings. J Pak Med Assoc. 2009, 59 (11): 744-747.PubMed
Metadata
Title
Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths
Authors
Mehnaz Jabeen
Mohammad Yawar Yakoob
Aamer Imdad
Zulfiqar A Bhutta
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Public Health / Issue Special Issue 3/2011
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-11-S3-S6

Other articles of this Special Issue 3/2011

BMC Public Health 3/2011 Go to the issue

Review

Effect of multiple micronutrient supplementation during pregnancy on maternal and birth outcomes

Review

Effect of balanced protein energy supplementation during pregnancy on birth outcomes

Review

Effect of routine iron supplementation with or without folic acid on anemia during pregnancy

Review

The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths

Methodology

Comparison of LiSTmeasles mortality model and WHO/IVB measles model

Review

Effect of screening and management of diabetes during pregnancy on stillbirths